Editorial: Defining the Role of Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC)
- 07.11.2025
- Peritoneal Surface Malignancy
- Verfasst von
- Zachary J. Brown, DO
- Erschienen in
- Annals of Surgical Oncology
Auszug
Peritoneal metastasis (PM) presents a formidable therapeutic challenge to both patients and providers, often rendering a dismal prognosis. For carefully selected patients, radical tumor extirpation with cytoreductive surgery (CRS) with or without hyperthermic intraperitoneal chemotherapy (HIPEC) may offer a survival benefit. However, those patients with unresectable disease are often consigned to palliative chemotherapy, which is often plagued by poor outcomes. This is often attributed to limited efficacy of systemic chemotherapy owing to poor vascular supply to the peritoneum and limited tissue penetration which often renders systemic chemotherapy less effective.1 Intraperitoneal (IP) delivery of chemotherapy was conceptualized nearly half a century ago and continues to evolve. …
Anzeige
- Titel
- Editorial: Defining the Role of Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC)
- Verfasst von
-
Zachary J. Brown, DO
- Publikationsdatum
- 07.11.2025
- Verlag
- Springer International Publishing
- Erschienen in
-
Annals of Surgical Oncology
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681 - DOI
- https://doi.org/10.1245/s10434-025-18650-6
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.
